On December 15, 2020 Genmab A/S (Nasdaq: GMAB) reported that at a board meeting the board decided to grant 9,663 restricted stock units to members of the board of directors and employees of the company as well as the company’s subsidiaries and 24,964 warrants to employees of the company and the company’s subsidiaries (Press release, Genmab, DEC 15, 2020, View Source [SID1234572870]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Each restricted stock unit is awarded cost-free and provides the owner with a right and obligation to receive one share in Genmab A/S of nominally DKK 1. The vesting of the restricted stock units granted to members of the board of directors will be subject to additional vesting criteria in the event of a change of control. The fair value of each restricted stock unit is equal to the closing market price on the date of grant of one Genmab A/S share, DKK 2,381.

The restricted stock units will vest on the first banking day of the month following a period of three years from the date of grant. Furthermore, the restricted stock units are subject to vesting conditions set out in the restricted stock unit program adopted by the board of directors in accordance with the Remuneration Policy adopted by the shareholders at the annual general meeting. Information concerning Genmab’s restricted stock unit program can be found on www.genmab.com under Investors > Stock information > Restricted stock units.

The exercise price for each warrant is DKK 2,381. Each warrant is awarded cost-free and entitles the owner to subscribe one share of nominally DKK 1 subject to payment of the exercise price. By application of the Black-Scholes formula, the fair value of each warrant can be calculated as DKK 754.05.

The warrants vest three years after the grant date, and all warrants expire at the seventh anniversary of the grant date. The new warrants have been granted on the terms and conditions set out in the warrant program adopted by the board of directors on March 28, 2017. Information concerning Genmab’s warrant schemes can be found on www.genmab.com under Investors > Stock information > Warrants.

On December 15, 2020 Singlera Genomics Inc. reported that it raised $150 million in Series B financing (Press release, Singlera Genomics, DEC 15, 2020, View Source [SID1234572893]). This round of financing was led by the CICC Kai Tak Innovative Biomedicine Fund, and co-led by Detong Capital and Furong Investment. The new group of investors also include Huamei International, Linden Asset Group, Wuxi Capital, FutureX Skyline Capital, Shanghai Free Trade Zone Fund, and initial investors from the Series A round such as Greenpine Capital, Prosperico Ventures, and Proxima Ventures joined with follow-on investment. Singlera will utilize this round of financing mainly to expand the company’s early cancer screening product research and development pipeline and focus on promoting product registration and commercialization, as well as expanding prospective studies into pan-cancer early screening.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Singlera was established in 2014 with a commitment to develop the next generation of genetic testing and molecular diagnostic technologies. By focusing on the development and application of non-invasive early screening and diagnosis technology, the company developed a patented methylation detection platform for early tumor diagnostics and prevention. The series B round of financing demonstrates Singlera’s strong scientific technology research and development strength and broad commercial development prospects.

In July 2020, Singlera and Fudan University published groundbreaking scientific research results, which used Singlera’s circulating tumor DNA (ctDNA) methylation multi-cancer screening technology PanSeer to validate early cancer detection in a large population cohort. After this round of financing, Singlera Genomics will continue to carry out large-scale pan-cancer early screening prospective studies.

Mr. Johny Zhang, co-founder and CEO of Singlera, said in a statement "we thank investors for their trust and support. I am honored that the innovative R&D, clinical transformation, and commercialization capabilities of Singlera have been recognized by top investors. This round of financing will help us further expand our product system and strengthen our strategic advantages and marketing capabilities in the field of early tumor screening and liquid biopsy. Cancer has been a major disease that impacts the entire world. Since its establishment 6 years ago, Singlera has been aiming to overcome early cancer screening and diagnosis. It has made a series of major breakthroughs in cancer early screening and early diagnostic technology. The next priority is to accelerate the commercialization of products so that these innovations can be applied to cancer prevention and treatment for hundreds of millions of people."

"Singlera has been committed to building an open and diversified ‘industry-university-research-medicine’ collaborative innovation ecosystem. In the past few years, we have cooperated with dozens of domestic and international scientific research institutes, hospitals and Pharmaceutical companies have carried out extensive cooperation, which has laid a huge advantage for us in basic research and application results transformation of early tumor screening and liquid biopsy," Professor Yuan Gao, co-founder and scientific advisor of Singlera, said in a statement. "We have developed early cancer screening and diagnostic technologies and products covering a variety of cancer types including lung, colorectal, liver, stomach, esophageal, pancreatic, and thyroid. This round of financing will help us carry out large-scale prospective studies and clinical trials".

On December 14, 2020 Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, reported that President and CEO Bryan Hanson and Executive Vice President and CFO Suky Upadhyay will be presenting at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 3:40 p.m. Eastern Time (Press release, Zimmer Holdings, DEC 14, 2020, View Source [SID1234572836]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation can be accessed via Zimmer Biomet’s Investor Relations website at https://investor.zimmerbiomet.com. The webcast will be archived for replay following the conference.

On December 14, 2020 Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, reported the closing of its underwritten public offering of 29,500,000 shares of its common stock, including the exercise in full by the underwriters of their option to purchase up to an additional 3,847,826 shares, at the public offering price of $5.75 per share (the Offering) (Press release, Curis, DEC 14, 2020, View Source [SID1234572801]). Curis expects the net proceeds from the Offering to be approximately $159.1 million, after deducting underwriting discounts and commissions and estimated offering expenses.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cantor Fitzgerald & Co. and JonesTrading Institutional Services LLC acted as joint book-runners for the Offering. H.C. Wainwright & Co., LLC and Laidlaw & Company (UK) Ltd. acted as co-lead managers.

Curis intends to use the net proceeds from the Offering, together with its existing cash and cash equivalents, to continue development of CA-4948, in collaboration with Aurigene, and CI-8893, in collaboration with ImmuNext, and for general working capital and capital expenditures. Curis estimates that the net proceeds from the Offering, together with its existing cash and cash equivalents, will enable it to fund its operating expenses and capital expenditure requirements into 2023.

The securities in the Offering were offered pursuant to a shelf registration statement on Form S-3 (File No. 333-224627) that was filed with the United States Securities and Exchange Commission ("SEC") on May 3, 2018, and declared effective by the SEC on May 17, 2018 and an additional registration statement on Form S-3 (File No. 333-251211) filed pursuant to Rule 462(b) which became automatically effective on December 9, 2020. The offering was made only by a means of a written prospectus and a prospectus supplement that form a part of the registration statement. A final prospectus supplement and accompanying prospectus relating to the Offering has been filed with the SEC and is available on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus may also be obtained by contacting Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Ave., 6th Floor, New York, New York 10022 or by email at [email protected].

The securities described above have not been qualified under any state blue sky laws. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

On December 14, 2020 AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, reported it has made significant progress in detecting pre-cancer diseases (Press release, Anpac Bio, DEC 14, 2020, View Source [SID1234572817]). This development was made via novel sensor design, sensor fabrication, detection process, signal collection, signal processing and proprietary algorithms, which has been validated in both multi-year retrospective and prospective, large sample and population studies. The Company recently completed a prospective large population screening of over 110,000 individuals (and over 150,000 samples throughout this study with some individuals tested multiple times over the years) using AnPac Bio’s Cancer Differentiation Analysis (CDA) technology. The follow-up study involved over ~ 13,000 individuals assessed with high cancer risk, medium cancer risk and low cancer risk using AnPac Bio’s CDA technology.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Initial results indicated that AnPac Bio CDA technology is capable of providing meaningful information while also screening out pre-cancer diseases, with over 20 types of pre-cancer diseases diagnosed following initial screening utilizing CDA technology and subsequent confirmation by hospital or physical testing center health check-ups. Of the over 20 types of screened out pre-cancer cases, thyroid nodule/tumor ranked number one and pulmonary nodule ranked number two, with about 92.5% confirmed pre-cancer patients in medium to high risk cancer groups. Of the ~ 13,000 individuals, AnPac screened out and confirmed pre-cancer cases at roughly 4.5 times of that of cancer cases, strongly demonstrating that AnPac Bio CDA technology is sensitive to detecting pre-cancer diseases and it could play a critical role in cancer prevention.

Developing a viable pre-cancer and early-stage cancer screening technology has been a long-term goal of global scientists. However, its development and progress has been relatively slow, despite years of heavy investment and efforts by leading scientists and research groups. One of key factors inhibiting breakthroughs in cancer detection has been the lack of previous involvement and contributions of leading semiconductor detection experts (with sensor signal collection and processing).

AnPac Bio consists of research and development team with extensive knowledge and experience in detection technologies including novel and advanced detection technologies including highly sensitive sensor design and fabrications, as well as small signal collection and processing. AnPac’s founder, Dr. Chris Yu, graduated from The Pennsylvania State University with a Ph. D. degree in novel detection technology which involved novel sensor design and fabrication, and small signal detection and processing. Mr. Du, vice president of research and development of AnPac Bio, has ten years of extensive integrated circuit (IC) processing and integration experience, which is critical in fabricating highly sensitive cancer detection sensors, at a New York Stock Exchange traded IC manufacturing company prior to joining AnPac Bio.

AnPac Bio has innovated and developed biophysics based detection technology (in which biophysical properties of blood are detected and analyzed) for pre-cancer disease and early stage cancer screening and detection. The Company is also one of the very first companies to champion multi-cancer detection idea and methodology. The employment of biophysical properties for cancer detection is novel and is an alternative approach to traditional methods, with advantages of being able to detect multiple cancer and pre-cancer types earlier, more cost effective, achieves higher sensitivity and specificity, and has relatively simple sample requirements and test procedures. Specifically, it could play an important role in democratizing cancer screening to large populations at an affordable cost.

Dr. Chris Yu, CEO and Chairman of AnPac Bio commented: "We are very pleased to have achieved this significant breakthrough in successfully detecting pre-cancer diseases, which is critical in cancer prevention and saving lives. From a commercialization perspective, this breakthrough has significant ramifications for market and customer needs, and revenue generation potential. AnPac Bio is very proud to be one of the first research groups to have achieved this important technical milestone, which will significantly expand AnPac Bio’s available market size and customer base, and play an important role in revenue generation for years to come."